Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
About this item
Full title
Author / Creator
Tutt, Andrew N.J , Garber, Judy E , Kaufman, Bella , Viale, Giuseppe , Fumagalli, Debora , Rastogi, Priya , Gelber, Richard D , de Azambuja, Evandro , Fielding, Anitra , Balmaña, Judith , Domchek, Susan M , Gelmon, Karen A , Hollingsworth, Simon J , Korde, Larissa A , Linderholm, Barbro , Bandos, Hanna , Senkus, Elżbieta , Suga, Jennifer M , Shao, Zhimin , Pippas, Andrew W , Nowecki, Zbigniew , Huzarski, Tomasz , Ganz, Patricia A , Lucas, Peter C , Baker, Nigel , Loibl, Sibylle , McConnell, Robin , Piccart, Martine , Schmutzler, Rita , Steger, Guenther G , Costantino, Joseph P , Arahmani, Amal , Wolmark, Norman , McFadden, Eleanor , Karantza, Vassiliki , Lakhani, Sunil R , Yothers, Greg , Campbell, Christine , Geyer, Charles E and OlympiA Clinical Trial Steering Committee and Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Among patients who had mutations in
BRCA1
or
BRCA2
and were at high risk for disease progression, those who were assigned to a year of olaparib adjuvant therapy had 3-year invasive disease–free survival of 86%, as compared with 77% among those who were assigned to placebo. Few patients stopped olaparib owing to side effects.
Alternative Titles
Full title
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Authors, Artists and Contributors
Author / Creator
Garber, Judy E
Kaufman, Bella
Viale, Giuseppe
Fumagalli, Debora
Rastogi, Priya
Gelber, Richard D
de Azambuja, Evandro
Fielding, Anitra
Balmaña, Judith
Domchek, Susan M
Gelmon, Karen A
Hollingsworth, Simon J
Korde, Larissa A
Linderholm, Barbro
Bandos, Hanna
Senkus, Elżbieta
Suga, Jennifer M
Shao, Zhimin
Pippas, Andrew W
Nowecki, Zbigniew
Huzarski, Tomasz
Ganz, Patricia A
Lucas, Peter C
Baker, Nigel
Loibl, Sibylle
McConnell, Robin
Piccart, Martine
Schmutzler, Rita
Steger, Guenther G
Costantino, Joseph P
Arahmani, Amal
Wolmark, Norman
McFadden, Eleanor
Karantza, Vassiliki
Lakhani, Sunil R
Yothers, Greg
Campbell, Christine
Geyer, Charles E
OlympiA Clinical Trial Steering Committee and Investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_gup_ub_gu_se_307007
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_gup_ub_gu_se_307007
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2105215
